Guard Therapeutics International AB (publ), formerly A1M Pharma AB, is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-25	SEK 1.550	-3.00%	2,138
26-06-24	SEK 1.598	-3.73%	14,979
26-06-23	SEK 1.660	+13.70%	38,963
26-06-22	SEK 1.460	-5.93%	7,903
26-06-18	SEK 1.552	+2.11%	12,223

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-06-25 EDT			5-day change	1st Jan Change
1.550 ^SEK	-3.00%		-0.13%	+5.44%

06-12	Guard Therapeutics Initiates Divestment of GTX Platform	MT
06-11	Guard Therapeutics to Acquire Disruptive Pharma in Reverse Takeover	MT

Market Cap	31.26M 3.22M 2.83M 2.61M 2.44M 4.57M 304M 4.65M 12.11M 150M 12.09M 11.82M 520M	P/E 2026 *	0.67x	P/E 2027 *	0.6x
Enterprise Value	-84.74M -8.73M -7.67M -7.06M -6.6M -12.39M -823M -12.61M -32.82M -406M -32.77M -32.05M -1.41B	EV / Sales 2026 *	-0.69x	EV / Sales 2027 *	-1.14x
Free-Float	65.85%	Yield 2026 *	-	Yield 2027 *	-

06-12	Guard Therapeutics Initiates Divestment of GTX Platform	MT
06-11	Guard Therapeutics to Acquire Disruptive Pharma in Reverse Takeover	MT
06-11	Guard Therapeutics announces reverse takeover and planned name change	FW
06-09	Disruptive Pharma Holding Ab entered into a conditional agreement to acquire Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction valued at SEK 61 million.	CI
05-11	Guard Therapeutics loss before and after tax SEK 6.4 mln	RE
05-11	Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
04-10	Three stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-31	Guard Therapeutics updates on strategic review	RE
03-31	Guard Therapeutics nears next phase of strategic review	FW
03-30	Guard Therapeutics International AB Provides Update on Strategic Review and Considers Multiple Strategic Alternatives	CI
02-20	Guard Therapeutics International net sales SEK 0 thousand	RE
02-20	Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

25-10-26	Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study	CI
25-09-11	Redeye Initiates Coverage of Guard Therapeutics with Target Value of SEK 43	FW

Guard Therapeutics International AB Stock

Stocks

GUARD

SE0021181559

Biotechnology & Medical Research

Valuation: Guard Therapeutics International AB

Chart: Guard Therapeutics International AB

Latest news : Guard Therapeutics International AB

Last Transcript: Guard Therapeutics International AB

Analysts' recommendations: Guard Therapeutics International AB

Press Releases: Guard Therapeutics International AB

News in other languages: Guard Therapeutics International AB

Quotes and Performance

Course Extremes

Managers and Directors: Guard Therapeutics International AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Guard Therapeutics Initiates Transaction Process for the GTX Platform	AQ
06-10	Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma	AQ
04-09	Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market	AQ
03-31	Guard Therapeutics provides update on strategic review	AQ
02-05	Guard Therapeutics Announces Changes to the Company’s Management Team	AQ

21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § 116 WpHG

1 day	-3.00%
1 week	-0.13%
Current month	+8.09%
1 month	+15.67%
3 months	+1.31%
6 months	+10.71%
Current year	+5.44%

1 week	1.45	1.79
1 month	1.25	2.14
Current year	0.88	2.35
1 year	0.88	27
3 years	0.88	49.8
5 years	0.88	112.5
10 years	0.88	3,050

Manager	Title	Age	Since
Tobias Larsson Agervald CEO	Chief Executive Officer	50	2019-01-14
Karin Botha DFI	Director of Finance/CFO	53	2020-09-13
Michael Reusch CTO	Chief Tech/Sci/R&D Officer	66	2021-12-31

Director	Title	Age	Since
Göran Forsberg BRD	Director/Board Member	63	2019-05-28
Johannes Hulthe BRD	Director/Board Member	56	2019-05-28
Johan Bygge CHM	Chairman	70	2021-04-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-02-27	Peter Gilmour	Free		1,344,000	0.2672%
23-02-27	Tobias Larsson Agervald	Free	Chief Executive Officer	9,450,000	1.8784%
23-02-27	Camilla Svanstrom	Free		756,000	0.1503%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUARD THERAPEUTICS INTERNATIONAL AB	-3.00%	-0.13%	-90.91%	-74.90%	3.3M
LONZA GROUP AG	+1.67%	+9.28%	-5.05%	+1.40%	45.45B
REVOLUTION MEDICINES, INC.	+4.95%	+9.31%	+363.86%	+598.16%	36.09B
IQVIA HOLDINGS INC.	+0.44%	+11.12%	+17.47%	-12.91%	30.98B
BEONE MEDICINES AG	-0.64%	+1.92%	+3.08%	+53.58%	30.81B
CELLTRION, INC.	+0.23%	-0.29%	+13.24%	+21.10%	24.62B
ASCENDIS PHARMA A/S	+9.90%	+13.32%	-	-	14.78B
MEDPACE HOLDINGS, INC.	+1.40%	+12.99%	+67.11%	+132.76%	14.65B
EUROFINS SCIENTIFIC SE	+1.88%	+8.59%	+13.76%	+20.68%	13.3B
IONIS PHARMACEUTICALS, INC.	+2.38%	+5.69%	+95.85%	+97.63%	12.65B
Average	+1.92%	+6.57%	+53.16%	+93.05%	22.33B
Weighted average by Cap.	+2.13%	+6.77%	+77.89%	+128.88%

	2026 *	2027 *
Net sales	123M 12.67M 11.13M 10.25M 9.59M 17.98M 1.2B 18.31M 47.64M 589M 47.57M 46.53M 2.05B	123M 12.67M 11.13M 10.25M 9.59M 17.98M 1.2B 18.31M 47.64M 589M 47.57M 46.53M 2.05B
Net income	51M 5.25M 4.61M 4.25M 3.97M 7.45M 496M 7.59M 19.75M 244M 19.72M 19.29M 849M	58M 5.97M 5.25M 4.83M 4.52M 8.48M 564M 8.63M 22.47M 278M 22.43M 21.94M 966M
Net Debt	-116M -11.95M -10.49M -9.67M -9.04M -16.95M -1.13B -17.27M -44.93M -556M -44.86M -43.88M -1.93B	-172M -17.71M -15.56M -14.34M -13.4M -25.14M -1.67B -25.6M -66.62M -824M -66.52M -65.06M -2.86B